Tealwood Asset Management Inc. boosted its stake in Allergan PLC (NYSE:AGN) by 5.3% during the second quarter, Holdings Channel reports. The firm owned 7,048 shares of the company’s stock after buying an additional 355 shares during the period. Tealwood Asset Management Inc.’s holdings in Allergan PLC were worth $1,629,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in AGN. Barnett & Company Inc. bought a new stake in shares of Allergan PLC during the first quarter worth $111,000. Livingston Group Asset Management CO operating as Southport Capital Management bought a new stake in shares of Allergan PLC during the second quarter worth $125,000. Trust Co. of Vermont boosted its stake in shares of Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock worth $126,000 after buying an additional 89 shares during the period. Integrated Investment Consultants LLC boosted its stake in shares of Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock worth $137,000 after buying an additional 154 shares during the period. Finally, High Point Bank & Trust Co. boosted its stake in shares of Allergan PLC by 19.9% in the second quarter. High Point Bank & Trust Co. now owns 692 shares of the company’s stock worth $160,000 after buying an additional 115 shares during the period. 85.20% of the stock is owned by institutional investors and hedge funds.
Allergan PLC (NYSE:AGN) traded up 1.76% during trading on Tuesday, reaching $227.94. 4,294,607 shares of the company’s stock were exchanged. The company’s 50 day moving average price is $237.35 and its 200-day moving average price is $237.14. The stock has a market capitalization of $90.25 billion, a price-to-earnings ratio of 21.70 and a beta of 0.81. Allergan PLC has a 52 week low of $195.50 and a 52 week high of $322.68.
Allergan PLC (NYSE:AGN) last announced its quarterly earnings data on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.34 by $0.01. The company had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $4.10 billion. Allergan PLC had a net margin of 28.06% and a return on equity of 7.67%. The business’s revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.41 EPS. On average, equities analysts expect that Allergan PLC will post $14.00 EPS for the current year.
A number of equities research analysts recently weighed in on AGN shares. Goldman Sachs Group Inc. reissued a “buy” rating on shares of Allergan PLC in a research report on Wednesday, July 6th. Leerink Swann upped their target price on shares of Allergan PLC from $272.00 to $294.00 and gave the company an “outperform” rating in a report on Wednesday, July 27th. JPMorgan Chase & Co. set a $325.00 target price on shares of Allergan PLC and gave the company a “buy” rating in a report on Friday, August 5th. Zacks Investment Research cut shares of Allergan PLC from a “buy” rating to a “hold” rating in a report on Tuesday, July 26th. Finally, Vetr raised shares of Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $285.60 target price for the company in a report on Monday, August 1st. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Allergan PLC currently has an average rating of “Buy” and a consensus target price of $302.23.
About Allergan PLC
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.